Jocelyn Urbano
Psychiatric/Mental Health · Fort Worth, TXNPI 1770037467
Payments from drug & device makers
Across 198 payments — averaging $52.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$924
- Johnson & Johnson$787
- AbbVie$739
- Neurocrine Biosciences, Inc.$722
- Novo Nordisk$642
- plus $6K from 29 others
What the payments were for
- Food & beverage$10,34199%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 36 | $1,078 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $924 |
| Johnson & Johnson | 14 | $787 |
| AbbVie | 26 | $739 |
| Neurocrine Biosciences, Inc. | 13 | $722 |
| Novo Nordisk | 6 | $642 |
| Otsuka America Pharmaceutical, Inc. | 8 | $485 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $472 |
| Corcept Therapeutics | 4 | $467 |
| Alkermes, Inc. | 7 | $431 |
| Axsome Therapeutics, Inc. | 3 | $363 |
| Boehringer Ingelheim | 3 | $311 |
| Dexcom, Inc. | 2 | $275 |
| GSK | 2 | $241 |
| Corium, LLC | 2 | $241 |
| Lilly USA, LLC | 2 | $200 |
| Ironshore Pharmaceuticals Inc. | 4 | $176 |
| Supernus Pharmaceuticals, Inc. | 3 | $158 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Bayer | 2 | $125 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $121 |
| Sanofi | 1 | $120 |
| Shield Therapeutics Inc | 1 | $120 |
| AstraZeneca | 1 | $118 |
| Sanofi-aventis U.S. LLC | 1 | $117 |
| Kyowa Kirin, Inc. | 1 | $110 |
| Sunovion Pharmaceuticals Inc. | 10 | $106 |
| Astellas Pharma US Inc | 1 | $105 |
| Hologic Sales And Service, LLC | 1 | $89 |
| Medtronic | 1 | $79 |
| Indivior Inc. | 3 | $59 |
| IBSA Pharma Inc. | 1 | $50 |
| Organon | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$942
- CAPLYTA$674
- INVEGA SUSTENNA$634
- AUSTEDO$597
- ARISTADA$500
- Korlym$467
- INGREZZA$380
- Auvelity$363
- DEXCOM G7 GSS (161)$275
- XIFAXAN$250
- AREXVY$241
- Azstarys$241
- REXULTI$236
- ABILIFY MAINTENA$234
- VRAYLAR$226
- DEXCOM STELO GLUCOSE BIOSENSOR$150
- JORNAY PM$125
- ARISTADA INITIO$125
- NEXLIZET$125
- NEXLETOL$125
How this compares
$10,413 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 37 | $3,532 |
| Quetiapine Fumarate | 40 | $934 |
| Hydroxyzine Hcl | 29 | $635 |
| Olanzapine | 26 | $542 |
| Prazosin Hcl | 17 | $520 |
| Buspirone Hcl | 25 | $431 |
| Trazodone Hcl | 67 | $393 |
| Duloxetine Hcl | 26 | $370 |
| Mirtazapine | 19 | $282 |
| Paroxetine Hcl | 11 | $220 |
| Hydroxyzine Pamoate | 19 | $201 |
| Bupropion XlBupropion Hcl | 13 | $183 |
| Fluoxetine Hcl | 15 | $147 |
| Doxepin Hcl | 13 | $143 |
| Risperidone | 17 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $200 | $54226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Fort Worth
- Tamekia ScaggsFort Worth$80K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.